What Is Enveric Biosciences, Inc. (ENVB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Enveric Biosciences, Inc. is potentially undervalued at its current price of $1.32. Based on our 13-model framework, Enveric Biosciences, Inc.'s intrinsic value is estimated at a composite fair value of $2.47 — representing +87.1% implied upside — with 7 out of 9 active models confirming this thesis. Model dispersion is worth noting: First Chicago targets $5.46 (+313.5%), versus Bayesian DCF at $1.01 (-23.6%). This +337.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ENVB?
9 of 13 models are currently active for ENVB. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates ENVB's intrinsic value at $1.01, implying -23.6% downside from the current price. See which stocks rank higher →
How Does ENVB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ENVB ranks #374 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Enveric Biosciences, Inc. competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ENVB a Value Trap?
CirclFi's Value Trap algorithm assigns ENVB a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Enveric Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Enveric Biosciences, Inc. is rated at 3.5/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.
The gap between the most bullish and bearish model spans +337.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ENVB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ENVB's 9 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad